Global pharma major Pfizer may price its vaccine lower in India than in the UK and the US, sources in the know said. The government in the recent past had indicated that India wouldn’t be keen to procure the Pfizer-BioNTech vaccine because of its high cost and the extreme cold chain requirement at minus 70 degree Celsius. Responding to the concern over the temperature requirement, a senior government official pointed out that India had cold chain infrastructure, owned by the Department of Agricultural Research and Education, that would be sufficient for a vaccine like the one developed by US-based Pfizer along with Germanys BioNTech.
Courtesyg: Google (photo)
